Lithium treatment in adults with acute myeloid leukemia receiving chemotherapy.
To determine whether lithium can shorten chemotherapy-induced neutropenia, 35 adult patients with newly diagnosed acute myeloid leukemia undergoing initial chemotherapy were randomized either to receive oral lithium started at the time of biopsy-proven hypoplasia or to receive no lithium. This study failed to show statistically significant shortening of the duration of chemotherapy-induced neutropenia in the lithium treatment group.
D000328:Adult; D000380:Agranulocytosis / Q000188:drug therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D007958:Leukocyte Count; D008094:Lithium / Q000627:therapeutic use*; D008297:Male; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy*; D011897:Random Allocation
D008094:Lithium